Molecular Neurobiology

, Volume 55, Issue 5, pp 3698–3708 | Cite as

Increased Expression of Brain-Derived Neurotrophic Factor Transcripts I and VI, cAMP Response Element Binding, and Glucocorticoid Receptor in the Cortex of Patients with Temporal Lobe Epilepsy

  • G. A. Martínez-Levy
  • L. Rocha
  • F. Rodríguez-Pineda
  • M. A. Alonso-Vanegas
  • A. Nani
  • R. M. Buentello-García
  • M. Briones-Velasco
  • D. San-Juan
  • J. Cienfuegos
  • C. S. Cruz-FuentesEmail author


A body of evidence supports a relevant role of brain-derived neurotrophic factor (BDNF) in temporal lobe epilepsy (TLE). Magnetic resonance data reveal that the cerebral atrophy extends to regions that are functionally and anatomically connected with the hippocampus, especially the temporal cortex. We previously reported an increased expression of BDNF messenger for the exon VI in the hippocampus of temporal lobe epilepsy patients compared to an autopsy control group. Altered levels of this particular transcript were also associated with pre-surgical use of certain psychotropic. We extended here our analysis of transcripts I, II, IV, and VI to the temporal cortex since this cerebral region holds intrinsic communication with the hippocampus and is structurally affected in patients with TLE. We also assayed the cyclic adenosine monophosphate response element-binding (CREB) and glucocorticoid receptor (GR) genes as there is experimental evidence of changes in their expression associated with BDNF and epilepsy. TLE and pre-surgical pharmacological treatment were considered as the primary clinical independent variables. Transcripts BDNF I and BDNF VI increased in the temporal cortex of patients with pharmacoresistant TLE. The expression of CREB and GR expression follow the same direction. Pre-surgical use of selective serotonin reuptake inhibitors, carbamazepine (CBZ) and valproate (VPA), was associated with the differential expression of specific BDNF transcripts and CREB and GR genes. These changes could have functional implication in the plasticity mechanisms related to temporal lobe epilepsy.


Pharmacoresistant epilepsy Temporal cortex BDNF CREB GR 



This article constitutes a partial requisite to obtain the Ph.D. grade in the postgraduate program of Biological Sciences at the National Autonomous University of Mexico (UNAM) for GAM-L. This study was supported the research fund of the National Institute of Psychiatry “Ramón de la Fuente Muñíz” Project IC142040.0. We would like to thank Jose Perez Luna for his technical help.

Compliance with Ethical Standards

All experiments were approved by the Ethics Committee of the National Institute of Neurology and Neurosurgery “Manuel Velasco Suarez” (INNNMVS) in Mexico City (project 70/12). Participants signed an informed consent.


  1. 1.
    Engel J, Wiliamson PD, Wieser H-G (1997) Chapter 231: mesial temporal lobe epilepsy in epilepsy: a comprehensive text book edited by Engel J., Pedley TA. Lippinccott-Raven Publishers, Philadelphia, pp. 2417–2424Google Scholar
  2. 2.
    Goldenberg MM (2010) Overview of drugs used for epilepsy and seizures. P&T A-peer Rev J Formulary Manag 35(7):392–415Google Scholar
  3. 3.
    Jardim AP, Neves RS, Caboclo LO et al (2012) Temporal lobe epilepsy with mesial temporal sclerosis: hippocampal neuronal loss as a predictor of surgical outcome. Arq Neuropsiquiatr 70(5):319–324PubMedCrossRefGoogle Scholar
  4. 4.
    Riederer F, Lanzenberger R, Kaya M et al (2008) Network atrophy in temporal lobe epilepsy: a voxel-based morphometry study. Neurology 71(6):419–425PubMedCrossRefGoogle Scholar
  5. 5.
    Bonilha L, Kobayashi E, Rorden C et al (2003) Medial temporal lobe atrophy in patients with refractory temporal lobe epilepsy. J Neurol Neurosurg Psychiatry 74(12):1627–1630PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Bonilha L, Rorden C, Castellano G et al (2004) Voxel-based morphometry reveals gray matter network atrophy in refractory medial temporal lobe epilepsy. Arch Neurol 61(9):1379–1384PubMedCrossRefGoogle Scholar
  7. 7.
    Mueller SG, Laxer KD, Cashdollar N et al (2006) Voxel-based optimized morphometry (VBM) of gray and white matter in temporal lobe epilepsy (TLE) with and without mesial temporal sclerosis. Epilepsia 47(5):900–907PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Bonilha L, Elm JJ, Edwards JC et al (2010) How common is brain atrophy in patients with medial temporal lobe epilepsy? Epilepsia 51(9):1774–1779PubMedCrossRefGoogle Scholar
  9. 9.
    Sutula TP, Hagen J, Pitkänen A (2003) Do epileptic seizures damage the brain? Curr Opin Neurol 16(2):189–195PubMedCrossRefGoogle Scholar
  10. 10.
    Croll SD, Suri C, Compton DL et al (1999) Brain-derived neurotrophic factor transgenic mice exhibit passive avoidance deficits, increased seizure severity and in vitro hyperexcitability in the hippocampus and entorhinal cortex. Neuroscience 93(4):1491–1506PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Xu B, Michalski B, Racine RJ et al (2004) The effects of brain-derived neurotrophic factor (BDNF) administration on kindling induction, Trk expression and seizure-related morphological changes. Neuroscience 126(3):521–531PubMedCrossRefGoogle Scholar
  12. 12.
    Liu G, Gu B, He XP et al (2013) Transient inhibition of TrkB kinase after status epilepticus prevents development of temporal lobe epilepsy. Neuron 79(1):31–38PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Paradiso B, Marconi P, Zucchini S et al (2009) Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc Natl Acad Sci U S A 106(17):7191–7196PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Paradiso B, Zucchini S, Su T et al (2011) Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus. Epilepsia 52(3):572–578PubMedCrossRefGoogle Scholar
  15. 15.
    Simonato M, Tongiorgi E, Kokaia M (2006) Angels and demons: neurotrophic factors and epilepsy. Trends Pharmacol Sci 27(12):631–638PubMedCrossRefGoogle Scholar
  16. 16.
    Hou X, Wang X, Zhang L (2010) Conditional downregulation of brain derived neurotrophic factor and tyrosine kinase receptor B blocks epileptogenesis in the human temporal lobe epilepsy hippocampus. Neurol India 58(1):29–34PubMedCrossRefGoogle Scholar
  17. 17.
    Takahashi M, Hayashi S, Kakita A et al (1999) Patients with temporal lobe epilepsy show an increase in brain-derived neurotrophic factor protein and its correlation with neuropeptide Y. Brain Res 818(2):579–582PubMedCrossRefGoogle Scholar
  18. 18.
    Murray KD, Isackson PJ, Eskin TA et al (2000) Altered mRNA expression for brain-derived neurotrophic factor and type II calcium/calmodulin-dependent protein kinase in the hippocampus of patients with intractable temporal lobe epilepsy. J Comp Neurol 418(4):411–422PubMedCrossRefGoogle Scholar
  19. 19.
    Mathern GW, Babb TL, Micevych PE et al (1997) Granule cell mRNA levels for BDNF, NGF, and NT-3 correlate with neuron losses or supragranular mossy fiber sprouting in the chronically damaged and epileptic human hippocampus. Mol Chem Neuropathol 30(1–2):53–76PubMedCrossRefGoogle Scholar
  20. 20.
    Wang L, Zhou C, Zhu Q et al (2010) Up-regulation of serum- and glucocorticoid-induced protein kinase 1 in the brain tissue of human and experimental epilepsy. Neurochem Int 57(8):899–905PubMedCrossRefGoogle Scholar
  21. 21.
    Hong Z, Li W, Qu B et al (2014) Serum brain-derived neurotrophic factor levels in epilepsy. Eur J Neurol 21(1):57–64PubMedCrossRefGoogle Scholar
  22. 22.
    Kandratavicius L, Monteiro MR, Assirati JA Jr et al (2013) Neurotrophins in mesial temporal lobe epilepsy with and without psychiatric comorbidities. J Neuropathol Exp Neurol 72(11):1029–1042PubMedCrossRefGoogle Scholar
  23. 23.
    Pruunsild P, Kazantseva A, Aid T et al (2007) Dissecting the human BDNF locus: bidirectional transcription, complex splicing and multiple promoters. Genomics 90(3):397–406PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Tongiorgi E, Domenici L, Simonato M (2006) What is the biological significance of BDNF mRNA targeting in the dendrites? Clues from epilepsy and cortical development. Mol Neurobiol 33(1):17–32PubMedCrossRefGoogle Scholar
  25. 25.
    Martínez-Levy GA, Rocha L, Lubin FD et al (2016) Increased expression of BDNF transcript with exon VI in hippocampi of patients with pharmaco-resistant temporal lobe epilepsy. Neuroscience 314:12–21PubMedCrossRefGoogle Scholar
  26. 26.
    Jeanneteau F, Chao MV (2013) Are BDNF and glucocorticoid activities calibrated? Neuroscience 239:173–195PubMedCrossRefGoogle Scholar
  27. 27.
    Numakawa T, Adachi N, Richards M et al (2013) Brain-derived neurotrophic factor and glucocorticoids: reciprocal influence on the central nervous system. Neuroscience 239:157–172PubMedCrossRefGoogle Scholar
  28. 28.
    Suri D, Vaidya VA (2013) Glucocorticoid regulation of brain-derived neurotrophic factor: relevance to hippocampal structural and functional plasticity. Neuroscience 239:196–213PubMedCrossRefGoogle Scholar
  29. 29.
    Lambert WM, Xu CF, Neubert TA et al (2013) Brain-derived neurotrophic factor signaling rewrites the glucocorticoid transcriptome via glucocorticoid receptor phosphorylation. Mol Cell Biol 33(18):3700–3714PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Koo JW, Mazei-Robison MS, LaPlant Q et al (2015) Epigenetic basis of opiate suppression of Bdnf gene expression in the ventral tegmental area. Nat Neurosci 18(3):415–422PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Tanis KQ, Duman RS, Newton SS (2008) CREB binding and activity in brain: regional specificity and induction by electroconvulsive seizure. Biol Psychiatry 63(7):710–720PubMedCrossRefGoogle Scholar
  32. 32.
    Zhu X, Dubey D, Bermudez C et al (2015) Suppressing cAMP response element-binding protein transcription shortens the duration of status epilepticus and decreases the number of spontaneous seizures in the pilocarpine model of epilepsy. Epilepsia 56(12):1870–1878PubMedCrossRefGoogle Scholar
  33. 33.
    Park SA, Kim TS, Choi KS et al (2003) Chronic activation of CREB and p90RSK in human epileptic hippocampus. Exp Mol Med 35(5):365–370PubMedCrossRefGoogle Scholar
  34. 34.
    Guo J, Wang H, Wang Q et al (2014) Expression of p-CREB and activity-dependent miR-132 in temporal lobe epilepsy. Int J Clin Exp Med 7(5):1297–1306PubMedPubMedCentralGoogle Scholar
  35. 35.
    Ridder S, Chourbaji S, Hellweg R et al (2005) Mice with genetically altered glucocorticoid receptor expression show altered sensitivity for stress-induced depressive reactions. J Neurosci 25(26):6243–6250PubMedCrossRefGoogle Scholar
  36. 36.
    Schulte-Herbrüggen O, Chourbaji S, Ridder S et al (2006) Stress-resistant mice overexpressing glucocorticoid receptors display enhanced BDNF in the amygdala and hippocampus with unchanged NGF and serotonergic function. Psychoneuroendocrinology 31(10):1266–1277PubMedCrossRefGoogle Scholar
  37. 37.
    Chen H, Lombès M, Le Menuet D (2017) Glucocorticoid receptor represses brain-derived neurotrophic factor expression in neuron-like cells. Mol Brain 10(1):12PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Galimberti CA, Magri F, Copello F et al (2005) Seizure frequency and cortisol and dehydroepiandrosterone sulfate (DHEAS) levels in women with epilepsy receiving antiepileptic drug treatment. Epilepsia 46(4):517–523PubMedCrossRefGoogle Scholar
  39. 39.
    Nakken KO, Solaas MH, Kjeldsen MJ et al (2005) Which seizure-precipitating factors do patients with epilepsy most frequently report? Epilepsy Behav 6(1):85–89PubMedCrossRefGoogle Scholar
  40. 40.
    Sperling MR, Schilling CA, Glosser D et al (2008) Self-perception of seizure precipitants and their relation to anxiety level, depression, and health locus of control in epilepsy. Seizure 17(4):302–307PubMedCrossRefGoogle Scholar
  41. 41.
    Anacker C, Zunszain PA, Carvalho LA et al (2012) The glucocorticoid receptor: pivot of depression and of antidepressant treatment? Psychoneuroendocrinology 36(3):415–425CrossRefGoogle Scholar
  42. 42.
    Maric NP, Adzic M (2013) Pharmacological modulation of HPA axis in depression—new avenues for potential therapeutic benefits. Psychiatr Danub 25(3):299–305PubMedGoogle Scholar
  43. 43.
    Herrero MJ, Blanch J, Peri JM et al (2003) A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population. Gen Hosp Psychiatry 25:277–283PubMedCrossRefGoogle Scholar
  44. 44.
    Gómez-Arias B, Crail-Meléndez D, López-Zapata R et al (2012) Severity of anxiety and depression are related to a higher perception of adverse effects of antiepileptic drugs. Seizure 21:588–594PubMedCrossRefGoogle Scholar
  45. 45.
    First Michael B, Spitzer, Robert L, et al (2002) Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edition. (SCID-I/P) New York: biometrics research, New York State Psychiatric InstituteGoogle Scholar
  46. 46.
    San-Juan D, Tapia CA, González-Aragón MF et al (2011) The prognostic role of electrocorticography in tailored temporal lobe surgery. Seizure 20:564–569PubMedCrossRefGoogle Scholar
  47. 47.
    Chomczynski P, Sacchi N (1987) Single step method of RNA isolation by acid guanidinium thiocyanate–phenol-chloroform extraction. Anal Biochem 1621(1):156–159CrossRefGoogle Scholar
  48. 48.
    Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3(6):1101–1108PubMedCrossRefGoogle Scholar
  49. 49.
    Ernfors P, Bengzon J, Kokaia Z et al (1991) Increased levels of messenger RNAs for neurotrophic factors in the brain during kindling epileptogenesis. Neuron 7(1):165–176PubMedCrossRefGoogle Scholar
  50. 50.
    Humpel C, Wetmore C, Olson L (1993) Regulation of brain-derived neurotrophic factor messenger RNA and protein at the cellular level in pentylenetetrazol-induced epileptic seizures. Neuroscience 53(4):909–918PubMedCrossRefGoogle Scholar
  51. 51.
    Vezzani A, Ravizza T, Moneta D et al (1999) Brain-derived neurotrophic factor immunoreactivity in the limbic system of rats after acute seizures and during spontaneous convulsions: temporal evolution of changes as compared to neuropeptide Y. Neuroscience 90(4):1445–1461PubMedCrossRefGoogle Scholar
  52. 52.
    Jiang X, Zhou J, Mash DC et al (2009) Human BDNF isoforms are differentially expressed in cocaine addicts and are sorted to the regulated secretory pathway independent of the Met66 substitution. NeuroMolecular Med 11(1):1–12PubMedCrossRefGoogle Scholar
  53. 53.
    Koppel I, Tuvikene J, Lekk I et al (2015) Efficient use of a translation start codon in BDNF exon I. J Neurochem 134(6):1015–1025PubMedCrossRefGoogle Scholar
  54. 54.
    Chiaruttini C, Sonego M, Baj G et al (2008) BDNF mRNA splice variants display activity-dependent targeting to distinct hippocampal laminae. Mol Cell Neurosci 37(1):11–19PubMedCrossRefGoogle Scholar
  55. 55.
    Aid T, Kazantseva A, Piirsoo M et al (2007) Mouse and rat BDNF structure and expression revisited. J Neurosci Res 85:525–535PubMedCrossRefGoogle Scholar
  56. 56.
    Aliaga EE, Mendoza I, Tapia-Arancibia L (2009) Distinct subcellular localization of BDNF transcripts in cultured hypothalamic neurons and modification by neuronal activation. J Neural Transm 116(1):23–32PubMedCrossRefGoogle Scholar
  57. 57.
    Baj G, Del Turco D, Schlaudraff J et al (2013) Regulation of the spatial code for BDNF mRNA isoforms in the rat hippocampus following pilocarpine-treatment: a systematic analysis using laser microdissection and quantitative real-time PCR. Hippocampus 23(5):413–423PubMedCrossRefGoogle Scholar
  58. 58.
    Baj G, D’Alessandro V, Musazzi L et al (2012) Physical exercise and antidepressants enhance BDNF targeting in hippocampal CA3 dendrites: further evidence of a spatial code for BDNF splice variants. Neuropsychopharmacology 37(7):1600–1611PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Maynard KR, Hobbs JW, Sukumar M et al (2017) Bdnf mRNA splice variants differentially impact CA1 and CA3 dendrite complexity and spine morphology in the hippocampus. Brain Struct Funct. doi: 10.1007/s00429-017-1405-3
  60. 60.
    Pruunsild P, Sepp M, Orav E et al (2011) Identification of cis-elements and transcription factors regulating neuronal activity-dependent transcription of human BDNF gene. J Neurosci 31(9):3295–3308PubMedCrossRefGoogle Scholar
  61. 61.
    Martínez-Levy GA, Cruz-Fuentes CS (2014) Genetic and epigenetic regulation of the brain-derived neurotrophic factor in the central nervous system. Yale J Biol Med 87(2):173–186PubMedPubMedCentralGoogle Scholar
  62. 62.
    Katanuma Y, Numakawa T, Adachi N et al (2014) Phencyclidine rapidly decreases neuronal mRNA of brain-derived neurotrophic factor. Synapse 68(6):257–265PubMedCrossRefGoogle Scholar
  63. 63.
    Moore AN, Waxham MN, Dash PK (1996) Neuronal activity increases the phosphorylation of the transcription factor cAMP response element-binding protein (CREB) in rat hippocampus and cortex. J Biol Chem 271(24):14214–14220PubMedCrossRefGoogle Scholar
  64. 64.
    Zhu X, Han X, Blendy JA et al (2012) Decreased CREB levels suppress epilepsy. Neurobiol Dis 45(1):253–263PubMedCrossRefGoogle Scholar
  65. 65.
    Rakhade SN, Yao B, Ahmed S et al (2005) A common pattern of persistent gene activation in human neocortical epileptic foci. Ann Neurol 58(5):736–747PubMedCrossRefGoogle Scholar
  66. 66.
    Beaumont TL, Yao B, Shah A et al (2012) Layer-specific CREB target gene induction in human neocortical epilepsy. J Neurosci 32(41):14389–14401PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Bao GS, Cheng XQ, Hua Y et al (2011) Changes of glucocorticoid receptor mRNA expression in basolateral amygdale-kindled rats. Chin Med J 124(17):2622–2627PubMedGoogle Scholar
  68. 68.
    Hwang IK, Lee YB, Yoo KY et al (2005) Seizure-induced changes of mineralocorticoid and glucocorticoid receptors in the hippocampus in seizure sensitive gerbils. Neurosci Res 53(1):14–24PubMedCrossRefGoogle Scholar
  69. 69.
    Clark M, Smith MA, Weiss SR et al (1994) Modulation of hippocampal glucocorticoid and mineralocorticoid receptor mRNA expression by amygdaloid kindling. Neuroendocrinology 59(5):451–456PubMedCrossRefGoogle Scholar
  70. 70.
    Nyakas C, De Kloet ER, Veldhuis HD et al (1983) Hippocampal corticosterone receptors and novelty-induced behavioral activity. Brain Res 288(1–2):219–228Google Scholar
  71. 71.
    Baj G, Leone E, Chao MV et al (2011) Spatial segregation of BDNF transcripts enables BDNF to differentially shape distinct dendritic compartments. Proc Natl Acad Sci U S A 108(40):16813–16818PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Lavebratt C, Trifunovski A, Persson AS et al (2006) Carbamazepine protects against megencephaly and abnormal expression of BDNF and Nogo signaling components in the mceph/mceph mouse. Neurobiol Dis 24(2):374–383PubMedCrossRefGoogle Scholar
  73. 73.
    Chang YC, Rapoport SI, Rao JS (2009) Chronic administration of mood stabilizers upregulates BDNF and bcl-2 expression levels in rat frontal cortex. Neurochem Res 34(3):536–541PubMedCrossRefGoogle Scholar
  74. 74.
    Yasuda S, Liang MH, Marinova Z et al (2009) The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 14(1):51–59PubMedCrossRefGoogle Scholar
  75. 75.
    Croce N, Mathé AA, Gelfo F et al (2014) Effects of lithium and valproic acid on BDNF protein and gene expression in an in vitro human neuron-like model of degeneration. J Psychopharmacol 28(10):964–972PubMedCrossRefGoogle Scholar
  76. 76.
    Park SW, Lee JG, Seo MK et al (2015) Effects of mood-stabilizing drugs on dendritic outgrowth and synaptic protein levels in primary hippocampal neurons. Bipolar Disord 17(3):278–290PubMedCrossRefGoogle Scholar
  77. 77.
    Varela RB, Valvassori SS, Lopes-Borges J et al (2015) Sodium butyrate and mood stabilizers block ouabain-induced hyperlocomotion and increase BDNF, NGF and GDNF levels in brain of Wistar rats. J Psychiatr Res 61:114–121PubMedCrossRefGoogle Scholar
  78. 78.
    Chen PS, Peng GS, Li G et al (2006) Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 11(12):1116–1125PubMedCrossRefGoogle Scholar
  79. 79.
    Fukuchi M, Nii T, Ishimaru N et al (2006) Valproic acid induces up- or down-regulation of gene expression responsible for the neuronal excitation and inhibition in rat cortical neurons through its epigenetic actions. Neurosci Res 65(1):35–43CrossRefGoogle Scholar
  80. 80.
    Almeida LE, Roby CD, Krueger BK (2014) Increased BDNF expression in fetal brain in the valproic acid model of autism. Mol Cell Neurosci 59:57–62PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Blümcke I, Coras R, Miyata H et al (2012) Defining clinico-neuropathological subtypes of mesial temporal lobe epilepsy with hippocampal sclerosis. Brain Pathol 22(3):402–411PubMedCrossRefGoogle Scholar
  82. 82.
    Tassi L, Meroni A, Deleo F et al (2009) Temporal lobe epilepsy: neuropathological and clinical correlations in 243 surgically treated patients. Epileptic Disord 11(4):281–292PubMedGoogle Scholar
  83. 83.
    Fauser S, Schulze-Bonhage A (2006) Epileptogenicity of cortical dysplasia in temporal lobe dual pathology: an electrophysiological study with invasive recordings. Brain 129(Pt 1):82–95PubMedCrossRefGoogle Scholar
  84. 84.
    Mai L, Jope RS, Li X (2002) BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents. J Neurochem 82(1):75–83PubMedCrossRefGoogle Scholar
  85. 85.
    Shen HY, Kalda A, Yu L et al (2008) Additive effects of histone deacetylase inhibitors and amphetamine on histone H4 acetylation, cAMP responsive element binding protein phosphorylation and DeltaFosB expression in the striatum and locomotor sensitization in mice. Neuroscience 157(3):644–655PubMedCrossRefGoogle Scholar
  86. 86.
    Errami M, Tassa AT, Galindo CL et al (2010) Carbamazepine alone and in combination with doxycycline attenuates isoproterenol-induced cardiac hypertrophy. Heart Int 5(1):e7PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Bhowmik M, Saini N, Vohora D (2014) Histamine H3 receptor antagonism by ABT-239 attenuates kainic acid induced excitotoxicity in mice. Brain Res 1581:129–140PubMedCrossRefGoogle Scholar
  88. 88.
    Tai YT, Lee WY, Lee FP et al (2014) Low dose of valproate improves motor function after traumatic brain injury. Biomed Res Int 2014:980657PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Long ZM, Zhao L, Jiang R et al (2015) Valproic acid modifies synaptic structure and accelerates neurite outgrowth via the glycogen synthase kinase-3β signaling pathway in an Alzheimer’s disease model. CNS Neurosci Ther 21(11):887–897PubMedCrossRefGoogle Scholar
  90. 90.
    Basta-Kaim A, Budziszewska B, Jaworska-Feil L et al (2003) Opposite effects of clozapine and sulpiride on the lipopolysaccharide-induced inhibition of the GR-mediated gene transcription in fibroblast cells. Pol J Pharmacol 55(6):1153–1158PubMedGoogle Scholar
  91. 91.
    Usui T, Saitoh Y, Komada F (2003) Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull 26(4):510–517PubMedCrossRefGoogle Scholar
  92. 92.
    Gajzer D, Ross J, Winder L et al (2016) Epigenetic and molecular signatures of cord blood CD34 (+) cells treated with histone deacetylase inhibitors. Vox Sang 110(1):79–89PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • G. A. Martínez-Levy
    • 1
  • L. Rocha
    • 2
  • F. Rodríguez-Pineda
    • 1
  • M. A. Alonso-Vanegas
    • 3
  • A. Nani
    • 1
  • R. M. Buentello-García
    • 3
  • M. Briones-Velasco
    • 1
  • D. San-Juan
    • 4
  • J. Cienfuegos
    • 3
  • C. S. Cruz-Fuentes
    • 1
    Email author
  1. 1.Department of GeneticsNational Institute of Psychiatry “Ramón de la Fuente Muñiz” (INPRFM)Mexico CityMexico
  2. 2.Department of Pharmacobiology, Center for Research and Advanced StudiesCINVESTAVMexico CityMexico
  3. 3.Neurosurgery SectionNational Institute of Neurology and Neurosurgery “Manuel Velasco Suárez” (INNNMVS)Mexico CityMexico
  4. 4.Clinical Research DepartmentNational Institute of Neurology and Neurosurgery “Manuel Velasco Suárez” (INNNMVS)Mexico CityMexico

Personalised recommendations